Merck & Company Inc (MRK)vsViemed Healthcare Inc (VMD)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
VMD
Viemed Healthcare Inc
$8.79
+0.46%
HEALTHCARE · Cap: $345.84M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 21972% more annual revenue ($66.57B vs $301.61M). VMD leads profitability with a 4.8% profit margin vs 4.8%. VMD appears more attractively valued with a PEG of 1.86. VMD earns a higher WallStSmart Score of 52/100 (C-).
MRK
Hold36
out of 100
Grade: F
VMD
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
+27.3%
Fair Value
$11.62
Current Price
$8.79
$2.83 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Revenue surging 23.9% year-over-year
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Expensive relative to growth rate
Moderate valuation
Smaller company, higher risk/reward
4.8% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : VMD
The strongest argument for VMD centers on Debt/Equity, Altman Z-Score, Price/Book. Revenue growth of 23.9% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : VMD
The primary concerns for VMD are PEG Ratio, P/E Ratio, Market Cap. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
MRK profiles as a value stock while VMD is a growth play — different risk/reward profiles.
VMD carries more volatility with a beta of 1.09 — expect wider price swings.
VMD is growing revenue faster at 23.9% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
VMD scores higher overall (52/100 vs 36/100) and 23.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Viemed Healthcare Inc
HEALTHCARE · MEDICAL DEVICES · USA
Viemed Healthcare, Inc. provides durable home medical equipment and post-acute respiratory health care services to patients in the United States. The company is headquartered in Lafayette, Louisiana.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?